Daiichi Sankyo
Tracked across 2 events · 16 articles · First seen Apr 13, 2026 · Last active May 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Tech
The United States — Food and Drug Administration has approved Trastuzumab deruxtecan, a drug jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, for two new indications in the treatment of HER2-positive early breast cancer.…
Impact: Daiichi Sankyo, as the discoverer and co-developer of Trastuzumab deruxtecan with AstraZeneca, benefits significantly from the FDA's expanded approval, enhancing its market position and potential earnings.
May 15, 2026 · 7 articles
Tech
Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has received two new approvals from the United States — Food and Drug Administration. These approvals are for the neoadjuvant…
Impact: Daiichi Sankyo discovered Trastuzumab deruxtecan and jointly developed and commercialized it with AstraZeneca. The new approvals will lead to milestone payments from AstraZeneca and Daiichi Sankyo recognizes sales of Trastuzumab deruxtecan in the U.S.
May 15, 2026 · 9 articles
95
Daiichi Sankyo received approval United States — Food and Drug AdministrationFDA Approves ENHERTU for...
80
AstraZeneca paid milestone payments Daiichi SankyoEnhertu FDA Approvals for...
70
Daiichi Sankyo recognized sales Trastuzumab deruxtecanEnhertu FDA Approvals for...
NEWSDESK
Track Daiichi Sankyo live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard